The earnings call reflects a strong performance with significant revenue growth and strategic advancements in pipeline and market expansion. The company shows a clear path to profitability with stable operating expenses and promising future opportunities. However, there are some dependencies on regulatory approvals and expectations for increased transplant rates.

Company Guidance -

Q3 2025

During the 2025 second-quarter earnings call, Syndax Pharmaceuticals provided guidance indicating robust commercial progress and pipeline execution, highlighting two first-in-class therapies, Revuforj and Niktimvo, with combined net product sales nearing $100 million in the first half of the year. Revuforj's net revenue grew 43% quarter-over-quarter to $28.6 million, despite 1/3 of patients pausing treatment for stem cell transplants, and is on track to reach 50% penetration of its 2,000 annual KMT2A acute leukemia patient target by year's end. Niktimvo generated $36.2 million in net revenue in its first full quarter, with over 4,000 infusions administered. Syndax anticipates profitability driven by these therapies, with operating expenses expected to remain stable over the next few years. Importantly, Revuforj's anticipated supplemental new drug application approval could expand its addressable U.S. market to over 6,000 patients and a $2 billion relapsed/refractory market opportunity.

Strong Revenue Growth and Market Penetration

Revuforj and Niktimvo sales reached nearly $100 million in the first half of 2025, significantly exceeding expectations. Revuforj net revenue increased 43% quarter-over-quarter to $28.6 million.

Successful Launch of Niktimvo

Niktimvo reported $36.2 million in net revenue for the second quarter, up from $13.6 million in the first two months of the launch, with strong initial market penetration.

Promising Pipeline Developments

Anticipated approval of supplemental new drug application (sNDA) for Revuforj in relapsed/refractory mutant NPM1 AML with a PDUFA action date of October 25, 2025.

Expansion into Frontline Settings

Enrollment underway for pivotal frontline trials for Revuforj in combination with venetoclax and azacitidine, with a U.S. market opportunity exceeding $5 billion.

Operational Stability and Profitability Path

Operating expenses expected to remain stable for the next few years, with a strong balance sheet and a clear path to profitability.

Syndax Pharmaceuticals (SNDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SNDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.72 / -	-0.98	―	―	―
Aug 04, 2025	2025 (Q2)	-1.02 / -0.83	-0.8	-3.75% (-0.03)
May 05, 2025	2025 (Q1)	-1.25 / -0.98	-0.85	-15.29% (-0.13)
Mar 03, 2025	2024 (Q4)	-0.84 / -1.10	-1	-10.00% (-0.10)
Nov 05, 2024	2024 (Q3)	-1.07 / -0.98	-0.73	-34.25% (-0.25)
Aug 01, 2024	2024 (Q2)	-0.91 / -0.80	-0.64	-25.00% (-0.16)
May 08, 2024	2024 (Q1)	-0.98 / -0.85	-0.59	-44.07% (-0.26)
Feb 27, 2024	2023 (Q4)	-0.97 / -1.00	-0.62	-61.29% (-0.38)
Nov 02, 2023	2023 (Q3)	-0.79 / -0.73	-0.58	-25.86% (-0.15)
Aug 03, 2023	2023 (Q2)	-0.72 / -0.64	-0.62	-3.23% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SNDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$10.38	$12.57	+21.10%
May 05, 2025	$13.57	$10.64	-21.59%
Mar 03, 2025	$15.64	$15.48	-1.02%
Nov 05, 2024	$19.69	$21.35	+8.43%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Syndax Pharmaceuticals Inc (SNDX) report earnings?

Syndax Pharmaceuticals Inc (SNDX) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Syndax Pharmaceuticals Inc (SNDX) earnings time?

Syndax Pharmaceuticals Inc (SNDX) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SNDX EPS forecast?

SNDX EPS forecast for the fiscal quarter 2025 (Q3) is -0.72.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing